A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
Clinical trial NCT07545044 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07545044
- Sponsor
- Shanghai JMT-Bio Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-30
- Primary completion
- 2027-05-29
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.